LUND, SWEDEN -- (MARKET WIRE) -- 05/11/2006 --

* All clinical projects progressing according to plan

* Patent application submitted related to the mode of action of quinoline compounds

* Partnership agreement signed with Chelsea Therapeutics for the I- 3D project

* Net sales: SEK 1.7 million (0.8)

* Operating loss: SEK 43.0 million (loss: 48.1)

* Loss after tax: SEK 47.4 million (loss: 53.4)

* Loss per share for the period: SEK 1.19 (loss: 1.54)

Active Biotech AB (corp. reg. no. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0) 46-19 20 00
Fax: +46 (0) 46-19 20 50

Active Biotech Interim Rep Jan-Mar 06:

http://hugin.info/1002/R/1050463/173791.pdf

Copyright © Hugin ASA 2006. All rights reserved.